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Abstract
Background. Blood pressure in pediatric dialyzed patients is under poor control.
Objectives. The aim of the study was to assess the strategy and efficacy of antihypertensive drugs used 
for the treatment of hypertension in pediatric dialyzed patients in 2013 in comparison with the data col-
lected in 2003/2004. The results have been viewed against present strategies of antihypertensive treatment 
in children. There is still limited data concerning the treatment of hypertension in dialyzed pediatric patients.
Material and methods. The study embraced 10 of 12 pediatric dialysis units in Poland treating 59 pe-
diatric patients (mean age – 132 months). Collected information included present antihypertensive treat-
ment with regard to drug classes and the dose of antihypertensive agent. The  treatment was regarded 
as effective if both systolic and diastolic values of blood pressure were below 1.64 SDS. The results from 
2013 were juxtaposed with previously analyzed data from a similar study on hypertension in dialyzed chil-
dren conducted in 2003/2004.
Results. Forty subjects have been provided with antihypertensive treatment. In monotherapy and poly-
therapy 50% of the subjects were treated with ACEI (enalapril and ramipril), 67.5% with amlodipine, 50% 
with beta-blockers. Only 10% of the subjects were treated with angiotensin II receptor blocker (losartan). 
Thirty percent of the subjects received furosemide, whereas 5% were given doxazosin. Antihypertensive 
drugs regarded as the 2nd and 3rd choice in treating high blood pressure (doxazosin, beta-blockers and 
furosemide) were applied as monotherapy in 46% of the patients. Satisfactory control of treated blood 
pressure was reached in 45% of them.
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Conclusions. Antihypertensive treatment in dialyzed children did not change significantly during the last decade with regard to the groups of drugs being used. 
Despite a wider feasibility of antihypertensive substances, the effectiveness of this therapy was still unsatisfactory.
Key words: children, treatment, arterial hypertension, dialysis
tailed medical history of primary kidney disease, renal 
failure, dialysis, hypertension and its treatment, as well as 
basic anthropometrical measures – weight, height, BMI, 
and the adequacy of dialysis. A patient was recognized as 
hypertensive when systolic and/or diastolic values were 
≥95th percentile (SDS ≥ 1.65) concerning gender, age and 
height. Calculation of SDS was made with the help of Ku-
laga’s growth charts, which were also used to adapt data 
from our previous 2003/2004 national survey.9–11 
We analyzed the data of 59 patients under the age 
of 18 years: 40 boys (67.8%,) and 19 girls (32.2%) who had 
been dialyzed for at least 3 months. From the group of ana-
lyzed patients we extrapolated 46 hypertensive children 
(77.97%). The  average age was 132 months for the hyper-
tensive patients (who were older as compared with the av-
erage age of normotensive patients and the average age of 
the whole group). The average duration of dialysis was 16 
months. 63.04% of patients were on peritoneal dialysis 
(PD), whereas 36.96 % were on chronic hemodialysis (HD). 
Among the PD patients over 95% were treated with auto-
mated PD. Comparing the data collected in 2003/2004 and 
in 2013 respectively, we noted no significant differences be-
tween age, gender, anthropometric measurements and the 
type of dialysis technique. A significant difference was re-
ported in mean duration of dialysis (p = 0.048) that proved 
to be shorter in 2013 and in mean incidence of hypertension 
(p = 0.05) that appeared to be higher in 2013 (Table 1).
Statistical analysis
Data was evaluated by the Kołogomorow-Smirnov 
normality test with Lilliefor’s correction. Results are ex-
pressed as median and 25th–75th interquartile range. 
Statistical comparisons between groups were made by 
2-sided unpaired t-test or Mann-Whitney test. The χ2 and 
Fisher exact tests were applied to compare the categorical 
variables. The p-value of less than 0.05 was considered sig-
nificant. A standard score (Z-Score) was used to express 
a  standard deviation from the mean. All analyses were 
completed using STATISTICA v. 12 (StatSoft Inc., USA).
Results
Antihypertensive treatment 
Out of 59 patients, 40 subjects have been given antihy-
pertensive treatment. 
In the analyzed group, we found that 20/40 (50%) sub-
jects were treated with ACE inhibitors, 27/40 (67.5%) sub-
Introduction
High blood pressure is a constant element of the sce-
nario observed in dialyzed patient with an occurrence 
up to 90%.1 Many trials showed that the mortality rate 
following cardiovascular disease in dialyzed patients 
far exceeds the mortality rate observed in the healthy 
population.2 Recent guidelines for the management 
of arterial hypertension put a lot of effort into implement-
ing a  proper diagnosis and treatment of hypertension 
in adults, yet little has been mentioned about hyperten-
sion in children.3 The  new JNC8 guidelines touch the 
problem of high blood pressure and chronic kidney dis-
ease in recommendation 4 and 8, but only in patients 
aged 18 or over.4 Recommendations on prevention, diag-
nosis and treatment of hypertension in children and ado-
lescents (published in 2009) have not been updated yet.5 
In  2011, Rachel et al. reviewed antihypertensive 
agents used by pediatricians in treating hypertension. 
Their meta-analysis showed that ACE inhibitors (angio-
tensin-converting-enzyme inhibitors) and ARBs (angio-
tensin II receptor blockers) had the strongest evidence to be 
administered in children with kidney disease.6 So far there 
has been limited data regarding the prevalence and treat-
ment of high blood pressure in dialyzed pediatric patients.
Despite the awareness of high incidence of hyperten-
sion among dialyzed pediatric patients, this population 
is  treated ineffectively or elevated blood pressure is un-
dertreated.7 Fluid overload, excessive sodium intake 
and refractory hypertension are regarded as the most 
common causes of hypertension on dialysis. The  study 
of  Tkaczyk et al. pointed to the fact that the incidence 
of hypertension in dialyzed children in Poland exceeded 
55%, whilst the effectiveness of antihypertensive treat-
ment was below 60%.8 Even though there are novel drugs 
for antihypertensive therapy, there is still insufficient 
data concerning minors. Thus, the aim of the study was 
to assess the current incidence of hypertension among 
the Polish pediatric dialysis patients as well as to evaluate 
the effectiveness of current treatment.
Material and methods
In  2013 we obtained data from 10 pediatric dialysis 
centers in Poland, compared to 13 centers in 2003/2004. 
Two units did not respond to the survey. The study data 
was gathered in the same manner as in 2003. The  pa-
tients were surveyed individually by a treating physician. 
The  questionnaire included questions concerning a  de-
Adv Clin Exp Med. 2017;26(8):1263–1268 1265
jects – with calcium channel blocker (CCB), 20/40 (50%) 
subjects – with beta-blockers (BB), 12/40 (30%) subjects – 
with diuretics, 4/40 (10%) subjects – with angiotensin II 
receptor blockers (ARB), and 2/40 (5%) subjects – with al-
pha-blockers. A single-agent antihypertensive therapy was 
applied in 13/40 (32.5%) patients, whereas a combination 
therapy, defined as a concomitant use of 2 or more low-
ering blood pressure agents, was applied to 27/40 (67.5%) 
subjects. The consignment of drugs used for treating hy-
pertension was similar to that reported in 2003/2004. 
In the group of ACE inhibitors, it was enalapril that played 
a pivotal role (12/20 (60%) subjects, mean dose 0.274 mg/kg 
per day), followed by ramipril (8/20 (40%) subjects, mean 
dose 2.188 mg/m2 per day). Amlodipine was the only cal-
cium channel blocker that was used by 27  subjects with 
a mean dose of 0.35 mg/kg per day. In the group of beta-
blockers, a key role was played by metoprolol and carvedilol 
(8/12 (66.7%) subjects with a mean dose 1.07 mg/kg and 6/12 
(50%) subjects with mean dose 0.72 mg/kg, respectively). 
A few patients were treated with acebutolol, atenolol and 
bisoprolol. Losartan was the only angiotensin II receptor 
blocker used by 4 patients (with mean dose of 2.12 mg/kg 
per day) and furosemide was the only diuretic used by 
12 subjects (with the mean dose of 2.84 mg/kg per day).
In  monotherapy amlodipine 5/13 (38.46%) and beta-
blockers 3/13 (23.08%) were the most frequently applied 
antihypertensive agents, whereas ACEI and doxazosin 
were equivalently used as the 3rd choice 2/13 (15.38%). 
In  2-drug, 3-drug and ≥4-drug therapy CCB was the 
leading antihypertensive agent (in 73.3%, 83.3% and 100%, 
respectively). In 2-drug therapy ACE inhibitor was used 
as the 2nd add-on, but in ≥4-drug therapy it was used as 
the 4th add-on. The intensification of treatment by adding 
supplementary antihypertensive drugs increased the role 
of beta-blockers and diuretic in targeting blood pressure. 
ARB was used as an add-on drug in 3-drug therapy, and 
it was noted that 1 of 27 subjects was treated with ACE 
inhibitors and ARB simultaneously. 
Drug allocation
Initial application of ACE inhibitors in monotherapy was 
significantly lower (p = 0.04) in 2013 as compared to the 
first-line treatment set up in 2003/2004. The overall use of 
ACE inhibitors was comparable (p = 0.16) both in 2013 and 
in 2003/2004. In 2013 an increasing role of ACE inhibitors 
in treating hypertension was marked only in polytherapy. 
The  frequency of use of furosemide as monotherapy 
was significantly higher (p  =  0.14) in 2013 than in the 
years 2003/2004. 
Our analysis revealed that beta-blockers were one of the 
major antihypertensive agents used in mono as  well as 
in polytherapy in 2013, whereas in 2003/2004 an increas-
ing priority of beta-blockers was demonstrated, but not 
until 3-drug and 4-drug treatment. There was no signifi-
cant difference in use of other groups of drugs between 
2013 and 2003/2004.
Efficacy of antihypertensive treatment
Our study indicated that in 61% of patients hyperten-
sion was treated inadequately (with BP values over 95th 
percentile (SDS ≥ 1.65), which is similar to the results ob-
tained in 2003/2004 (65%). Within 10 years (Table 2), the 
level of underdiagnosed hypertension remained the same 
(10.2% vs 11.2%).
As compared to the results of Z-score in patients given 
antihypertensive treatment, systolic and diastolic blood 
pressure values were assigned as normotensive only in 18/40 
(45%) subjects. 22/40 (55%) patients remained hypertensive, 
which suggests that they were treated inadequately. What is 
more, Z-score results showed that in the group of patients 
considered as normotensive, 6/19 (31.58%) of subjects were 
found to have elevated isolated systolic or diastolic blood 
pressure, and 3 of them had abnormally elevated values both 
in systolic and diastolic pressure. 
In the group of hypertensive ineffectively treated sub-
jects, isolated abnormal systolic blood pressure was dia- 
gnosed in 3/40 patients, whereas isolated abnormal dia-
stolic pressure was noted in 13/40 patients. Six out of 40 
patients were hypertensive both in systolic and diastolic 
blood pressure. 
Table 1. Main anthropometric and clinical parameters of 2 analyzed 
cohorts of dialyzed children in the years 2003/2004–2013; data presented 
as median value and 25th–75th interquartile range
Clinical 
parameters
2013
n = 59
2003/2004
n = 134
Statistical 
difference
Age (months) 128 (61–171) 142 (76–175) ns
M:F ratio 40:19 (2.1:1) 89:45 (2:1) ns
PD:HD ratio 37:22 (1.7:1) 89:45 (2:1) ns
Duration of 
dialysis (months)
16 (6–27) 19 (8–40) 0.048
Height (cm) 125 (102–149) 135 (107–150) ns
Height SDS -2.2 (-3.4 to -1.0) -2 (-3.5 to -1.3) ns
Weight (kg) 24 (14.6–39.7) 29 (18–39) ns
Weight SDS -1.3 (-1.9 to -0.7) -1 (-2.1–0.8) ns
BMI (kg/m2) 16.4 (14.7–18.6) 16 (15–18) ns
BMI SDS -0.5 (-1.1 to -0.03) -1 (-1.1 to -0.1) ns
Table 2. Comparison of blood pressure values between cohorts of 
dialyzed pediatric patients in the years 2003/2004-2013
Clinical  
manifestation
2013
n = 59
2003/2004
n = 134
Statistical 
difference
Incidence of 
hypertension
46/59 (78%) 86/134 (64%) 0.05
Uncontrolled 
hypertension 
(percentage of 
hypertensive patients)
28/46 (61%) 56/86 (65%) ns
Underdiagnosed 
hypertension
6/59 (10.2%)
15/134 
(11.2%)
ns
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cially those that could be administered once a day. Beyond 
doubt, both ramipril and enalapril have been studied in hy-
pertensive children; however, ramipril was the agent stud-
ied in pediatric patients with chronic kidney disease that 
demonstrated good efficacy in lowering blood pressure 
in this particular group.13–16 As compared to similar stud-
ies, the mean daily dose of enalapril was 0.274 mg/kg, which 
was within the recommended range (0.08–0.6  mg/kg 
per day). As there is no dose referenced to age for ramipril, 
this ACE inhibitor was administered at a  mean dose 
of 2.188 mg per day, which just moderately exceeded the 
minimal recommended dose (2.5–6 mg per day).17
Angiotensin II receptor blocker
The only angiotensin II receptor blocker used in antihy-
pertensive therapy was losartan, though used infrequently 
in 2014 and 2003/2004 (respectively 4/40 and 6/72 pa-
tients). Despite the fact that losartan was used as an add-on 
therapy with a mean dose 2.12 mg/kg per day far beyond 
exceeding the recommended initial dose (0.75–1.44 mg/kg 
per day), a total efficacy of such a combined treatment was 
received only in 10% (1/10 subjects). The inclusion of ARB 
into preexisting therapy resulted in 1 case of simultaneous 
treatment with ACEI and ARB. ONTARGET Trial showed 
that the combination of ACE inhibitors and ARB pre-
scribed for patients with renal dysfunction does not reduce 
poor outcomes, and may lead to more adverse drug-related 
events.18 Losartan has to be dosed twice a day, which may 
alter proper compliance with the patient. Although trials 
with long acting ARB were conducted in very small groups 
of pediatric patients, valsartan seems to have the most suf-
ficient data for its effectiveness in lowering blood pressure 
in young children, yet was not in use.19
Beta-blockers
Beta-blockers are one of the most frequently chosen drugs 
in monotherapy in 2013 (20/40 patients vs 26/72 patients 
in 2003/2004). The choice of drugs remained the same for 
10 years except for labetalol that was not assigned in 2013, 
undeniably due to its unavailability in  Poland. Hence, it 
seems that labetalol was replaced with metoprolol. 
Diuretics
The only diuretic that was used in 2013 and 2003 was 
furosemide, but exclusively in 2014 it was used as mono-
therapy in 1/40 hypertensive patient. 
Alpha-blockers
There is very limited data supporting the use of al-
pha-blockers as antihypertensive agents in children. 
What is more, alpha-blockers may lead to several side ef-
fects such as drowsiness. Our analysis showed that alpha-
The  effectiveness of hypertensive treatment in mono-
therapy was achieved in 7/13 (53.84%) subjects, and in poly-
therapy in 11/27 (40.74%) subjects, whereas in 2003/2004 
it  totaled 16/24 (66.67%) and 14/46 (30.43%) subjects, re-
spectively. While comparing the results from 2013 with 
the results obtained in 2003/2004, no significant differ-
ence has been found in the efficacyof treatment, both in 
monotherapy (p = 0.19) and in polytherapy (p = 0.26). This 
finding leads to a conclusion that the rate of adequate con-
trol of blood pressure has not changed as yet.
Among 22 patients with ineffectively controlled blood 
pressure only 6 (23.3%) were treated with ≥3-drug ther-
apy. It  is to be noted that 16/22 (73%) patients were not 
treated by means of all available methods of lowering 
blood pressure. 
Discussion
The  incidence of hypertension in dialyzed children is 
still underestimated due to the lack of sufficient data. Mist-
nefes et al. revealed that 76.6% of dialyzed children were 
hypertensive, and Kramer AM et al. found that among 
pediatric patients on renal replacement therapy (RRT) 
in Europe the prevalence of hypertension accounts for 
54.4%.7,12 These results are in accordance with our results 
from 2013, which marked the incidence of hypertension 
at the level of 77.97%, and last but not least, the incidence 
significantly increased by ca. 14% (p = 0.05) as compared 
with the previous observation from 2003/2004. 
Referring to our previous 2003/2004 report, one of the 
aims of this study was to elucidate thoroughly the drug allo-
cation in mono and in polytherapy. In our work we centered 
on the evaluation of doctors’ approach to antihypertensive 
treatment in dialyzed children in the last 10 years. Conse-
quent to this, which might be regarded as a weakness, the 
paper itself does not deal with the causes of hypertension, 
the type of dialysis filters, underlying diseases and co-mor-
bid factors. Yet, such an in-depth analysis is unique as com-
pared to similar studies that have been published, which 
constitutes a remarkable strength of this work.
Angiotensin-converting enzyme (ACE) 
inhibitors
ACE inhibitors play a  crucial role in treating hyper-
tension. Captopril, with its in-depth study in children, 
is believed to be safe and effective in lowering high blood 
pressure; however, it has a short period of activity, which 
is why it has to be administered 2–3 times per day. The us-
age of captopril both in previous and present analysis was 
scarce (1 patient in respective years). In  2014 enalapril 
was assigned to 57.14% and ramipril to 38.09% of patients, 
whilst in 2003/2004 enalapril was assigned to 88.63% 
and ramipril to 2.27%. Our data shows that newer classes 
of  ACE inhibitors were infrequently reached for, espe-
Adv Clin Exp Med. 2017;26(8):1263–1268 1267
Finally, in the group of ineffectively treated hypertensive 
subjects 32.5% presented an isolated abnormal diastolic 
blood pressure (DBP), which might lead to a conclusion that 
being focused on systolic pressure, diastolic blood pressure 
seems to be overlooked. There are 2 hypotheses on the pres-
ence of isolated diastolic hypertension in dialyzed popula-
tion. First of all, this may be related to improper measure-
ment when DBP seems to be overestimated by the traditional 
techniques of measuring.28 However, in dialyzed patients 
isolated abnormal DBP should not be neglected, as it may be 
related to a significant fluid overload and sympathetic over-
activity. Recent but scarce data suggests that in dialyzed pa-
tients strict fluid management during renal replacement the- 
rapy can significantly reduce DBP within the following 
months of treatment.29,30 Such a  fact may indicate that in 
a population of dialyzed patients isolated DBP can be indi-
rect evidence for fluid overload that, in the state of preserved 
diuresis, could actually require an assignment of diuretics.31 
Nevertheless, this group of drugs should be supported with 
some of the cardioprotective agents.
New scopes for better  
blood pressure control
Our analysis highlights 2 major problems. First and 
foremost, it is essential to identify all hypertensive pa-
tients. In the present study, 13% of patients were underdia- 
gnosed and subsequently their elevated blood pressure 
was not treated at all. Secondly, appropriate antihyper-
tensive therapy should rely on evidence-based treatment 
as well as on pathophysiology of hypertension. As elevat-
ed blood pressure in dialyzed patients depends on renin-
angiotensin system overactivity (due to increased levels 
of angiotensin II, renin and renal ischemia), it seems that 
in antihypertensive therapy ACE inhibitors application 
should be prioritized. ACE inhibitors reduce left ven-
tricular mass and decrease the mean arterial blood pres-
sure.32,33 In  hypertensive pediatric dialyzed population, 
renal artery stenosis is not frequent, and other contra-
indications, such as pregnancy and breast-feeding, can 
be neglected. Thus, this group of drugs both with ARB 
seems to be the safest. Our study showed that ACE in-
hibitors were used in monotherapy only in 15.38%. 
In  hypertensive children not on dialysis, good blood 
pressure control may be achieved by long-acting ARBs; 
however, none of them was in use in the analyzed group 
of patients.19 As there is an increased level of angiotensin II 
that provokes sympathetic activity, beta-blockers can play 
an important role in better hypertension control as long 
as their dialyzability rate is taken into account. In hyper-
volemic dialyzed patients with preserved diuresis blood 
pressure target might be achieved by the administration 
of loop diuretics.33 Long-acting dihydropyridine calcium 
channel blockers are as safe as ACEI inhibitors, contrary 
to non-dihydropiridine that can amplify the effect of si-
multaneously administered beta-blockers. Recent studies 
blockers (here uniquely doxazosin) were used as mono-
therapy in 15.38% of treated patients, unlike in the years 
2003/2004 when the assignment of alpha-blockers was ob-
served only in a 3-drug therapy and 4-drug therapy.
General comments
Ineffective antihypertensive therapy might be attributed 
to dialysis-related removal of certain drugs. When choos-
ing a  proper antihypertensive therapy, it is important to 
take into consideration the potential removal of  these 
agents from the circulation by hemodialysis, as well as by 
peritoneal dialysis. Whilst doses of antibiotics are adjusted 
to intermittent renal replacement therapy procedures, the 
dialyzability of blood pressure lowering agents is usually 
disrespected. It is worth pointing out that among ACE in-
hibitors captopril, enalapril and among beta-blockers ace-
butolol, atenolol and metoprolol are removed by hemodi-
alysis.20 Our study showed that 29% hypertensive patients 
underwent hemodialysis and 49% underwent peritoneal 
dialysis. Peritoneal dialysis, except for certain antibiotics, 
provides minor drug removal. The level of dialyzability in 
this type of RRT depends on the low volume of distribu-
tion and high protein bound. The volume of distribution 
of enalapril is 1.7 L/kg and plasma protein binding is 60%, 
thereby being eliminated by peritoneal dialysis.21–25 By con-
trast, the protein binding of captopril is about 30% and the 
volume of distribution of ramipril totals over 90 L/kg.21–25 
In this way, neither ramipril nor losartan, carvedilol, doxa-
zosin and furosemide are partially eliminated by standard, 
low-flux or peritoneal renal replacement therapy. Both 
enalapril and captopril are particularly recommended 
to be administered post-HD. Our analysis showed that 
among the categories of assigned antihypertensive drugs 
that undergo dialysis: ACE inhibitors comprised 61.9% 
(enalapril and captopril) and beta-blockers – 65% (acebuto-
lol, atenolol and metoprolol).21–25 Thirty-one percent of pa-
tients that underwent peritoneal dialysis were treated with 
enalapril. Incidentally, it is worth pointing out that recent 
studies showed the association between dialysis-related re-
moval of beta-blockers and a higher risk of death in elderly 
hemodialyzed patients.26 In our study, 11.8% of hemodia-
lyzed hypertensive patients received in monotherapy beta-
blocker that is eliminated by this type of RRT. 
Ineffective antihypertensive therapy might also be at-
tributed to low compliance that depends not only on the 
number of tablets taken per day, but also on the taste 
of the drugs. As most of antihypertensive agents do not 
exist in pediatric formulations, proper adjustment of the 
pediatric dose of the drug to the patient requires dividing 
it or smashing it to smaller particles. The taste of broken 
tablets is not accepted by children, except for hydrochlo-
rothiazide, lercanidipine and candesartan, which are 
tasteless.27 With respect to pediatric population, the in-
fluence of the taste of tablets on the level of compliance 
should be, in our opinion, further investigated.
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on pediatric population showed that when administered in 
monotherapy, the effectiveness of long-acting dihydropyri-
dine calcium channel blockers in reducing systolic as well 
as diastolic blood pressure is weak. On the other hand, this 
was the most willingly chosen group of  drugs in mono-
therapy (38.46%), which was pointed out in our analysis.
Is there a place for other groups of drugs?
Startling as it may seem, lately it has been noted that 
the application of spironolactone in dialyzed patients has 
considerably decreased an all-cause cardiovascular mor-
tality rate. The  study embraced adult population; how- 
ever, the application of spironolactone as diuretic and 
cardioprotective agent in part of pediatric population 
with myocardial hypertrophy is still worth poring over. 
There was no higher incidence of hyperkaliemia in this 
dialyzed patients treated with spironolactone and its ef-
fect as antihypertensive agent was weak.34 
Conclusions
Despite good accessibility of novel formulas in portfo-
lio of antihypertensive drugs, the treatment of hyperten-
sion in 2013 has not changed much, as compared to the 
data collected in 2003/2004. Long-acting ACE inhibitors 
and ARB, being safe and effective, should play a pivotal 
role in antihypertensive treatment of dialyzed children 
and other agents should be used as adjunct therapy. 
Owing to multiple cardiovascular complications, greater 
effort should be put into early identification of hyperten-
sive pediatric patients on dialysis.
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